AORT

Artivion, Inc.

18.07 USD

Last updated Dec 3, 01:28 UTC

Yesterday HIGH

$18.11

Yesterday LOW

$17.57

52w HIGH

$18.11

52w LOW

$11.39

EPS

0.02

PE

903.50

Next Earnings

Feb 15, 2024

Overview News Insider Transactions Government Trades

Artivion, Inc. stock is up 39.54% since 30 days ago. The next earnings date is Feb 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 51.61% of the previous 30 December’s closed higher than November. 100% of analysts rate it a buy.

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases.

Stock Exchange

NYSE

Sector

Manufacturing

Industry

Medical Equipment

Headquarters

Kennesaw, United States Of America

Website

artivion.com

Benzinga Newsdesk

Thu May 4, 2023

Artivion Q1 EPS $0.02 Beats $(0.12) Estimate, Sales $83.23M Beat $80.35M Estimate

Artivion (NYSE:AORT) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.12) by 116.67 percent. This is a 33.33 percent decrease over earnings of $0.03 per share from the same
Benzinga Insights

Thu May 4, 2023

Artivion: Q1 Earnings Insights
Benzinga Insights

Thu May 4, 2023

Earnings Scheduled For May 4, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
Benzinga Newsdesk

Fri Feb 17, 2023

Needham Maintains Buy on Artivion, Maintains $23 Price Target

Needham analyst Mike Matson maintains Artivion (NYSE:AORT) with a Buy and maintains $23 price target.
Bill Haddad

Thu Feb 16, 2023

Artivion Sees FY23 Revenues $331M-$343M vs $337.95M Est.
Bill Haddad

Thu Feb 16, 2023

Artivion Q4 EPS $0.10 Beats $(0.12) Estimate, Sales $79.40M Miss $79.85M Estimate

Artivion (NYSE:AORT) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.12) by 183.33 percent. The company reported quarterly sales of $79.40 million which missed the analyst
Benzinga Insights

Thu Feb 16, 2023

Earnings Scheduled For February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year 2022.
Lisa Levin

Fri Nov 4, 2022

Under Armour To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
Benzinga Newsdesk

Fri Nov 4, 2022

Needham Maintains Buy on Artivion, Lowers Price Target to $23

Needham analyst Mike Matson maintains Artivion (NYSE:AORT) with a Buy and lowers the price target from $28 to $23.
Benzinga Newsdesk

Thu Nov 3, 2022

Artivion Q3 EPS $(0.05) Beats $(0.11) Estimate, Sales $76.80M Beat $76.19M Estimate

Artivion (NYSE:AORT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.11) by 54.55 percent. This is a 66.67 percent decrease over losses of $(0.03) per share from the same

Needham

Fri Nov 3, 06:51

buy

confirm

Advanced Data Unlock

Horton Amy, VP, Chief Accounting Officer

Mon Nov 27, 2023

AORT Recent Insider Trades and Stock Chart

2,101 shares sold
Horton Amy, VP, Chief Accounting Officer

Mon Nov 27, 2023

AORT Recent Insider Trades and Stock Chart

1,750 shares gifted